H.R. 8339: Drug Origin Transparency Act of 2026

This bill, known as the Drug Origin Transparency Act of 2026, seeks to improve the reporting and labeling of drug manufacturing and supply chain information to enhance transparency in the pharmaceutical industry. Below are the key provisions of the bill:

Enhanced Drug Manufacturing Reporting

The bill amends the existing Federal Food, Drug, and Cosmetic Act to require more detailed reporting by drug manufacturers regarding the sources of their ingredients. Specifically, it mandates that:

• Drug manufacturers must report additional information about their suppliers, including the identity of suppliers for active pharmaceutical ingredients and the amounts of the drug made using these ingredients.
• Reports must be submitted more frequently than once a year, with a schedule set by the Secretary of Health and Human Services; submissions can occur up to four times a year.
• Additional reporting requirements will not take effect until at least six months after new regulations are issued.

Drug Labeling Requirements

The bill also stipulates new labeling requirements for drugs and active pharmaceutical ingredients. These requirements include:

• Labels must include the name, place of business, and unique identification of the original manufacturer of the drug or active pharmaceutical ingredient.
• If multiple manufacturers are involved, the labels must identify each manufacturer and the packer or distributor.
• The bill allows the Secretary to propose reasonable variations or different placements for these labeling requirements, including the use of electronic formats.

Purpose of the Bill

The overall aim of this legislation is to improve transparency in the pharmaceutical supply chain. By requiring detailed information about the origins of drugs and their components, the bill intends to facilitate better oversight of drug manufacturing practices, potentially increasing safety and accountability in the pharmaceutical industry.

Relevant Companies

• PFE (Pfizer Inc.): As a major pharmaceutical company, Pfizer may need to adjust its reporting and labeling practices to comply with the new requirements outlined in this bill.
• MRK (Merck & Co., Inc.): Merck is likely to be affected as it may have to enhance its reporting mechanisms to include detailed supplier information and comply with new labeling mandates.
• ABT (Abbott Laboratories): Abbott may face changes in its manufacturing processes and labeling practices to ensure compliance with enhanced transparency regulations.